Withholding/withdrawing treatment from neonates: legislation and official guidelines across Europe

H E McHaffie1, M Cuttini, G Brölz-Voit

  • 1University of Edinburgh, Scotland.

Journal of Medical Ethics
|January 15, 2000
PubMed

Insights

European countries generally agree on limiting aggressive neonatal treatment when cure is impossible, prioritizing compassionate care. Active euthanasia for neonates is prohibited, though some Dutch pediatricians assist in ending life in specific intractable cases.

Area of Science:

  • Medical Ethics
  • Neonatal Care
  • European Law

Background:

  • Decision-making for neonates involves complex legal, ethical, and professional considerations across Europe.
  • Varying approaches exist regarding the limitation of medical treatment for critically ill newborns.

Purpose of the Study:

  • To compare legal, ethical, and professional frameworks for neonatal decision-making in eight European countries.
  • To identify commonalities and divergences in practices related to treatment limitation and end-of-life care for neonates.

Main Methods:

  • Comparative legal and ethical analysis.
  • Review of national policies and case law across eight European nations.
  • Examination of professional guidelines and reported practices.

Main Results:

  • General consensus exists on discouraging overly aggressive treatment for neonates when cure is not possible.
  • Widespread acceptance of limiting aggressive treatment or alleviating suffering when a neonate's death is inevitable.
  • Debate surrounds limiting treatment for neonates with bleak prognoses, with limited legal challenges.
  • Active, intentional ending of neonatal life is legally prohibited across Europe, with a noted exception in Dutch practice under specific conditions.

Conclusions:

  • While active euthanasia for neonates is prohibited in Europe, Dutch pediatricians report instances of assisted dying with parental consent in intractable situations.
  • There is a shared emphasis on compassionate care and avoiding futile, aggressive interventions in neonatal end-of-life decisions.
  • Legal and ethical frameworks for neonatal end-of-life care show both convergence and divergence across European countries, necessitating ongoing discussion and policy refinement.

Related Concept Videos

Ethical Standards II01:23

Ethical Standards II

Ethical standards are the backbone of nursing practice, guiding nurses as they interact with patients, families, and colleagues. These standards are crucial for providing safe, empathetic care centered on the patient's needs.
Nurses are entrusted with upholding various ethical principles and standards. Nurses forge solid therapeutic relationships using trust, empathy, autonomy, confidentiality, and professional competence.
Confidentiality is crucial, embodying respect for individual privacy and...
Ethical Dilemmas I01:17

Ethical Dilemmas I

Ethical dilemmas in nursing are of utmost importance, as they often arise from the tension between adhering to core ethical principles and the practical realities of healthcare delivery. These dilemmas require nurses to navigate complex situations where competing ethical considerations pull them in different directions.
Let us explore some examples to understand the potentially complex moral decisions nurses face.
Take the case of caring for minors, particularly in areas related to reproductive...
Drug Regulation01:25

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
Drug Control Governance: Regulatory Bodies and Their Impact01:03

Drug Control Governance: Regulatory Bodies and Their Impact

Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with a...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...